F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies

Investigational New Drugs

Volumn 28, Issue 2, 2010, Pages 132-138

  Li, Jing ^a   Meng, Yang ^a   Liu, Yue ^a   Feng, Zhi Qiang ^a   Chen, Xiao Guang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Apoptosis; Epidermal growth factor receptor inhibitors; F84; Gynecologic malignancies; PD153035

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; F 84; N (3 BROMOPHENYL) N [7 METHOXY 6 (3 MORPHOLINOPROPOXY)QUINAZOLIN 4 YL] 3,3 DIMETHYLBUTANAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BODY WEIGHT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; ORGAN SIZE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952242534     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9225-9     Document Type: Article

References (23)

1. A Jemal 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 10.3322/canjclin.57.1.43 17237035
2. WP McGuire 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer N Engl J Med 334 1 6 10.1056/NEJM199601043340101 1:CAS:528:DyaK28XhtFKiur4%3D 7494563 (Pubitemid 26012496)
3. S Ashouri AA Garcia 2007 Current status of signal transduction modulators in the treatment of gynecologic malignancies Curr Treat Options Oncol 8 6 383 392 10.1007/s11864-007-0051-z 18196458
4. S Bellone G Frera G Landolifi 2007 Overexpression of epidermal growth factor typr-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease Gynecol Oncol 106 3 513 520 10.1016/j.ygyno.2007.04.028 1:CAS:528:DC%2BD2sXhtVSjsrnE 17540437 (Pubitemid 47302461)
5. GE Kim YB Kim NH Cho HC Chung HR Pyo JD Lee 2004 Synchronous co-expression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival Clin Cancer Res 10 4 1366 1374 10.1158/1078-0432.CCR-0497-03 1:CAS:528: DC%2BD2cXhsVGjs7w%3D 14977838 (Pubitemid 38365230)
6. J Schlessinger 2002 Ligand-induced, receptor-mediated dimerization and activation of EGF receptor Cell 110 669 672 10.1016/S0092-8674(02)00966-2 1:CAS:528:DC%2BD38XnsFKis7w%3D 12297041 (Pubitemid 35283957)
7. J Schlessinger 2000 Cell signaling by receptor tyrosine kinases Cell 103 211 225 10.1016/S0092-8674(00)00114-8 1:CAS:528:DC%2BD3cXns1Cltrs%3D 11057895
8. DW Fry AJ Kraker A McMichael LA Ambroso JM Nelson WR Leopold 1994 A specific inhibitor of the epidermal growth factor receptor tyrosine kinase Science 265 1093 1095 10.1126/science.8066447 1:CAS:528:DyaK1cXjvFyisA%3D%3D 8066447
9. DH Boschelli 2002 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors Curr Top Med Chem 2 9 1051 1063 10.2174/1568026023393354 1:CAS:528:DC%2BD38XmtVOitbk%3D 12171571
10. M Bos J Mendelsohn YM Kim J Albanell DW Fry J Baselga 1997 PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner Clin Cancer Res 3 11 2099 2106 1:CAS:528:DyaK2sXns1OgtrY%3D 9815602
11. J Marshall 2006 Clinical implications of the mechanism of epidermal growth factor receptor inhibitors Cancer 107 6 1207 1218 10.1002/cncr.22133 1:CAS:528:DC%2BD28XhtVOns7zP 16909423 (Pubitemid 44452768)
12. RJ Schilder MW Sill X Chen 2005 Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study Clin Cancer Res 11 5539 5548 10.1158/1078-0432.CCR-05-0462 1:CAS:528:DC%2BD2MXmvFSmurg%3D 16061871 (Pubitemid 41060831)
13. J Baselga D Rischin M Ranson, et al. 2002 Phase I safety, pharmacokinetic and pharmacodynamic trial of ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types J Clin Oncol 20 4292 4302 10.1200/JCO.2002.03.100 1:CAS:528:DC%2BD38Xpt1CjtLo%3D 12409327 (Pubitemid 35266289)
14. BM Slomovitz RL Coleman C Levenback, et al. 2006 Phase I study of weekly topotecan and gefitinib in patients with platinum resistant ovarian, peritoneal or fallopian tube cancer J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 24 Suppl. 5090
15. R Hariprasad L Kumar R Patnaik A Gupta S Kumar 2006 Maintenance therapy in epithelial ovarian cancer (EOC): could EGFR inhibitor-gefitinib be a candidate drug? A pilot study J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 24 Suppl. 15046
16. RI Nicholson JM Gee ME Harper 2001 EGFR and cancer prognosis Eur J Cancer 37 suppl 4 S9 S15 10.1016/S0959-8049(01)00231-3 1:CAS:528:DC%2BD3MXntlOku7w%3D 11597399
17. JM Sewell KG Macleod A Ritchie JF Smyth SP Langdon 2002 Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD1839 ("Iressa") Br J Cancer 86 3 456 462 10.1038/sj.bjc.6600058 1:CAS:528:DC%2BD38XisFOls7Y%3D 11875715 (Pubitemid 34185133)
18. J Vermeij E Teugels C Bourgain J Xiangming P in't Veld V Ghislain B Neyns J De Grève 2008 Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers BMC Cancer 8 3 10.1186/1471-2407-8-3 18182111 (Pubitemid 351386043)
19. L Lacroix P Pautier P Duvillard N Motte P Saulnier JM Bidart JC Soria 2006 Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations Int J Cancer 118 4 1068 1069 10.1002/ijc.21460 1:CAS:528:DC%2BD28Xhtlaisbs%3D 16152583 (Pubitemid 43157690)
20. F Rivera ME Vega-Villegas MF López-Brea 2008 Cetuximab, its clinical use and future perspectives Anticancer Drugs 19 2 99 113 10.1097/CAD.0b013e3282f23287 1:CAS:528:DC%2BD1cXitVSjug%3D%3D 18176106
21. MJ Palayekar TJ Herzog 2008 The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer Int J Gynecol Cancer 8 5 879 890 10.1111/j.1525-1438.2007.01144.x
22. JR Woodburn 1999 The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol Ther 82 241 250 10.1016/S0163-7258(98)00045-X 1:CAS:528:DyaK1MXjvFOhtLw%3D 10454201 (Pubitemid 29255919)
23. F Ciardiello G Tortora 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7 2958 2970 1:CAS:528:DC%2BD3MXnvF2ktbk%3D 11595683